868 related articles for article (PubMed ID: 26210353)
41. [Expression of SDF-1 gene in bone marrow mesenchymal stem cells of patients with myelodysplastic syndrome].
Zhang YZ; DA WM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr; 14(2):281-4. PubMed ID: 16638197
[TBL] [Abstract][Full Text] [Related]
42. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes.
Shetty V; Mundle S; Alvi S; Showel M; Broady-Robinson L; Dar S; Borok R; Showel J; Gregory S; Rifkin S; Gezer S; Parcharidou A; Venugopal P; Shah R; Hernandez B; Klein M; Alston D; Robin E; Dominquez C; Raza A
Leuk Res; 1996; 20(11-12):891-900. PubMed ID: 9009245
[TBL] [Abstract][Full Text] [Related]
43. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
Maratheftis CI; Bolaraki PE; Voulgarelis M
Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
[TBL] [Abstract][Full Text] [Related]
44. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.
Bernasconi P
Br J Haematol; 2008 Sep; 142(5):695-708. PubMed ID: 18540941
[TBL] [Abstract][Full Text] [Related]
45. [Change of cytokine expressions on bone marrow mesenchymal stem cells in patients with bone marrow failure syndromes and its significance].
Yang SM; Lu SF; Fei XM; Zhang JF; Shen WY; Li JY; Lu H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1560-3. PubMed ID: 21176370
[TBL] [Abstract][Full Text] [Related]
46. Increased Ripk1-mediated bone marrow necroptosis leads to myelodysplasia and bone marrow failure in mice.
Wagner PN; Shi Q; Salisbury-Ruf CT; Zou J; Savona MR; Fedoriw Y; Zinkel SS
Blood; 2019 Jan; 133(2):107-120. PubMed ID: 30413413
[TBL] [Abstract][Full Text] [Related]
47. Germline mutations in the bone marrow microenvironment and dysregulated hematopoiesis.
Miller LH; Qu CK; Pauly M
Exp Hematol; 2018 Oct; 66():17-26. PubMed ID: 30076950
[TBL] [Abstract][Full Text] [Related]
48. Deregulated microRNA expression and its pathogenetic implications for myelodysplastic syndromes.
Kuang X; Chi J; Wang L
Hematology; 2016 Dec; 21(10):593-602. PubMed ID: 27357100
[TBL] [Abstract][Full Text] [Related]
49. Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes.
Xing T; Yao WL; Zhao HY; Wang J; Zhang YY; Lv M; Xu LP; Zhang XH; Huang XJ; Kong Y
J Cell Physiol; 2024 Feb; 239(2):e31129. PubMed ID: 38192063
[TBL] [Abstract][Full Text] [Related]
50. Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes.
Falconi G; Fabiani E; Fianchi L; Criscuolo M; Raffaelli CS; Bellesi S; Hohaus S; Voso MT; D'Alò F; Leone G
Exp Hematol; 2016 Jan; 44(1):75-83.e1-4. PubMed ID: 26521017
[TBL] [Abstract][Full Text] [Related]
51. In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome.
Flores-Figueroa E; Gutiérrez-Espíndola G; Montesinos JJ; Arana-Trejo RM; Mayani H
Leuk Res; 2002 Jul; 26(7):677-86. PubMed ID: 12008086
[TBL] [Abstract][Full Text] [Related]
52. Bone marrow niches in myeloid neoplasms.
Kitagawa M; Kurata M; Onishi I; Yamamoto K
Pathol Int; 2020 Feb; 70(2):63-71. PubMed ID: 31709722
[TBL] [Abstract][Full Text] [Related]
53. Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.
Balaian E; Weidner H; Wobus M; Baschant U; Jacobi A; Mies A; Bornhäuser M; Guck J; Hofbauer LC; Rauner M; Platzbecker U
Ann Hematol; 2019 Sep; 98(9):2063-2072. PubMed ID: 31312928
[TBL] [Abstract][Full Text] [Related]
54. Myelodysplastic syndromes.
Zhou J; Orazi A; Czader MB
Semin Diagn Pathol; 2011 Nov; 28(4):258-72. PubMed ID: 22195404
[TBL] [Abstract][Full Text] [Related]
55. DNA demethylating therapy reverts mesenchymal stromal cells derived from high risk myelodysplastic patients to a normal phenotype.
Maurizi G; Mattiucci D; Mariani M; Ciarlantini M; Traini S; Mancini S; Olivieri A; Leoni P; Poloni A
Br J Haematol; 2017 Jun; 177(5):818-822. PubMed ID: 27102230
[No Abstract] [Full Text] [Related]
56. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.
Gañán-Gómez I; Wei Y; Starczynowski DT; Colla S; Yang H; Cabrero-Calvo M; Bohannan ZS; Verma A; Steidl U; Garcia-Manero G
Leukemia; 2015 Jul; 29(7):1458-69. PubMed ID: 25761935
[TBL] [Abstract][Full Text] [Related]
57. Hematopoiesis-related microRNA expression in myelodysplastic syndromes.
Pons A; Nomdedeu B; Navarro A; Gaya A; Gel B; Diaz T; Valera S; Rozman M; Belkaid M; Montserrat E; Monzo M
Leuk Lymphoma; 2009 Nov; 50(11):1854-9. PubMed ID: 19883312
[TBL] [Abstract][Full Text] [Related]
58. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS.
Follo MY; Marmiroli S; Faenza I; Fiume R; Ramazzotti G; Martelli AM; Gobbi P; McCubrey JA; Finelli C; Manzoli FA; Cocco L
Adv Biol Regul; 2013 Jan; 53(1):2-7. PubMed ID: 23058275
[TBL] [Abstract][Full Text] [Related]
59. Gene expression profiling in the myelodysplastic syndromes.
Pellagatti A; Fidler C; Wainscoat JS; Boultwood J
Hematology; 2005 Aug; 10(4):281-7. PubMed ID: 16085540
[TBL] [Abstract][Full Text] [Related]
60. Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis.
Kunze K; Gamerdinger U; Leßig-Owlanj J; Sorokina M; Brobeil A; Tur MK; Blau W; Burchardt A; Käbisch A; Schliesser G; Kiehl M; Rosenwald A; Rummel M; Grimminger F; Hain T; Chakraborty T; Bräuninger A; Gattenlöhner S
Pathol Res Pract; 2014 Jun; 210(6):369-76. PubMed ID: 24674452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
